Lakeside Advisors’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$568K Buy
1,348
+2
+0.1% +$797 0.33% 47
2026
Q2
$487K Buy
1,346
+3
+0.2% +$1.03K 0.31% 50
2026
Q1
$472K Buy
1,343
+3
+0.2% +$1.07K 0.32% 45
2025
Q4
$439K Buy
1,340
+33
+3% +$10.5K 0.28% 46
2025
Q3
$369K Buy
1,307
+3
+0.2% +$870 0.23% 47
2025
Q2
$364K Buy
1,304
+3
+0.2% +$850 0.23% 47
2025
Q1
$405K Buy
1,301
+3
+0.2% +$886 0.27% 44
2024
Q4
$338K Buy
1,298
+203
+19% +$60.2K 0.22% 51
2024
Q3
$353K Buy
1,095
+2
+0.2% +$654 0.22% 51
2024
Q2
$341K Buy
1,093
+3
+0.3% +$881 0.22% 52
2024
Q1
$310K Buy
1,090
+3
+0.3% +$878 0.2% 52
2023
Q4
$313K Buy
1,087
+2
+0.2% +$545 0.22% 50
2023
Q3
$291K Buy
1,085
+3
+0.3% +$749 0.22% 50
2023
Q2
$240K Buy
1,082
+4
+0.4% +$928 0.18% 52
2023
Q1
$261K Buy
1,078
+3
+0.3% +$736 0.2% 51
2022
Q4
$282K Buy
1,075
+2
+0.2% +$536 0.23% 49
2022
Q3
$242K Buy
1,073
+3
+0.3% +$727 0.22% 50
2022
Q2
$260K Buy
1,070
+116
+12% +$28.4K 0.22% 51
2022
Q1
$231K Sell
954
-199
-17% -$45.7K 0.17% 54
2021
Q4
$259K Buy
+1,153
New +$243K 0.19% 47

Other funds holding AMGN

Lakeside Advisors's AMGN Position: Q3 2026 in Review

Lakeside Advisors increased its Amgen (AMGN) stake by 0.15% in Q3 2026, buying an estimated $797 and bringing the position to 1,348 shares worth $568K. The position accounts for 0.33% of the portfolio, ranked #47.

Lakeside Advisors first reported a position in AMGN in Q4 2021 and has held it in 20 quarters since. 2,617 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • Lakeside Advisors held 1,348 shares of Amgen worth $568K as of Q3 2026.
  • Lakeside Advisors bought 2 Amgen shares in Q3 2026, an estimated $797.
  • Amgen made up 0.33% of Lakeside Advisors's portfolio in Q3 2026, its #47 holding.
  • Lakeside Advisors first reported a position in Amgen in Q4 2021 and has held it in 20 quarters since.
  • 2,617 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on Lakeside Advisors's 13F filing for Q3 2026, filed 20 Oct 2026.